0001209191-19-030172.txt : 20190515
0001209191-19-030172.hdr.sgml : 20190515
20190515192335
ACCESSION NUMBER: 0001209191-19-030172
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190513
FILED AS OF DATE: 20190515
DATE AS OF CHANGE: 20190515
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bozigian Haig P.
CENTRAL INDEX KEY: 0001423837
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 19830251
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-13
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001423837
Bozigian Haig P.
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Development Officer
Common Stock
2019-05-13
4
M
0
34547
8.66
A
176523
D
Common Stock
2019-05-13
4
S
0
34547
75.5149
D
141976
D
Non-Qualified Stock Option
8.66
2019-05-13
4
M
0
34547
8.66
A
2022-01-12
Common Stock
34547
0
D
Includes 337 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2019.
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $74.26 to $77.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Option granted January 12, 2012 and vested monthly over four years.
/s/ Darin Lippoldt, Attorney-in-Fact
2019-05-15